Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Fabry Disease Treatment Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Enzyme Replacement Therapy (ERT)
  • 1.4.3 Chaperone Treatment
  • 1.4.4 Substrate Reduction Therapy (SRT)
  • 1.4.5 Others
• 1.5 Market by Application
  • 1.5.1 Global Fabry Disease Treatment Market Share by Application (2014-2025)
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Fabry Disease Treatment Market Size
• 2.2 Fabry Disease Treatment Growth Trends by Regions
  • 2.2.1 Fabry Disease Treatment Market Size by Regions (2014-2025)
  • 2.2.2 Fabry Disease Treatment Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Fabry Disease Treatment Market Size by Manufacturers
  • 3.1.1 Global Fabry Disease Treatment Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Fabry Disease Treatment Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Fabry Disease Treatment Market Concentration Ratio (CR5 and HHI)
• 3.2 Fabry Disease Treatment Key Players Head office and Area Served
• 3.3 Key Players Fabry Disease Treatment Product/Solution/Service
• 3.4 Date of Enter into Fabry Disease Treatment Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Fabry Disease Treatment Market Size by Type (2014-2019)
• 4.2 Global Fabry Disease Treatment Market Size by Application (2014-2019)

5 United States

• 5.1 United States Fabry Disease Treatment Market Size (2014-2019)
• 5.2 Fabry Disease Treatment Key Players in United States
• 5.3 United States Fabry Disease Treatment Market Size by Type
• 5.4 United States Fabry Disease Treatment Market Size by Application

6 Europe

• 6.1 Europe Fabry Disease Treatment Market Size (2014-2019)
• 6.2 Fabry Disease Treatment Key Players in Europe
• 6.3 Europe Fabry Disease Treatment Market Size by Type
• 6.4 Europe Fabry Disease Treatment Market Size by Application

7 China

• 7.1 China Fabry Disease Treatment Market Size (2014-2019)
• 7.2 Fabry Disease Treatment Key Players in China
• 7.3 China Fabry Disease Treatment Market Size by Type
• 7.4 China Fabry Disease Treatment Market Size by Application

8 Japan

• 8.1 Japan Fabry Disease Treatment Market Size (2014-2019)
• 8.2 Fabry Disease Treatment Key Players in Japan
• 8.3 Japan Fabry Disease Treatment Market Size by Type
• 8.4 Japan Fabry Disease Treatment Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Fabry Disease Treatment Market Size (2014-2019)
• 9.2 Fabry Disease Treatment Key Players in Southeast Asia
• 9.3 Southeast Asia Fabry Disease Treatment Market Size by Type
• 9.4 Southeast Asia Fabry Disease Treatment Market Size by Application

10 India

• 10.1 India Fabry Disease Treatment Market Size (2014-2019)
• 10.2 Fabry Disease Treatment Key Players in India
• 10.3 India Fabry Disease Treatment Market Size by Type
• 10.4 India Fabry Disease Treatment Market Size by Application

11 Central & South America

• 11.1 Central & South America Fabry Disease Treatment Market Size (2014-2019)
• 11.2 Fabry Disease Treatment Key Players in Central & South America
• 11.3 Central & South America Fabry Disease Treatment Market Size by Type
• 11.4 Central & South America Fabry Disease Treatment Market Size by Application

12 International Players Profiles

• 12.1 Sanofi S.A.
  • 12.1.1 Sanofi S.A. Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Fabry Disease Treatment Introduction
  • 12.1.4 Sanofi S.A. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.1.5 Sanofi S.A. Recent Development
• 12.2 Shire Plc.
  • 12.2.1 Shire Plc. Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Fabry Disease Treatment Introduction
  • 12.2.4 Shire Plc. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.2.5 Shire Plc. Recent Development
• 12.3 Amicus Therapeutics Inc.
  • 12.3.1 Amicus Therapeutics Inc. Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Fabry Disease Treatment Introduction
  • 12.3.4 Amicus Therapeutics Inc. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.3.5 Amicus Therapeutics Inc. Recent Development
• 12.4 ISU Abxis Co Ltd.
  • 12.4.1 ISU Abxis Co Ltd. Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Fabry Disease Treatment Introduction
  • 12.4.4 ISU Abxis Co Ltd. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.4.5 ISU Abxis Co Ltd. Recent Development
• 12.5 JCR Pharmaceuticals Co Ltd.
  • 12.5.1 JCR Pharmaceuticals Co Ltd. Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Fabry Disease Treatment Introduction
  • 12.5.4 JCR Pharmaceuticals Co Ltd. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.5.5 JCR Pharmaceuticals Co Ltd. Recent Development
• 12.6 Protalix Biotherapeutics Inc.
  • 12.6.1 Protalix Biotherapeutics Inc. Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Fabry Disease Treatment Introduction
  • 12.6.4 Protalix Biotherapeutics Inc. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.6.5 Protalix Biotherapeutics Inc. Recent Development
• 12.7 Idorsia Pharmaceuticals Ltd.
  • 12.7.1 Idorsia Pharmaceuticals Ltd. Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Fabry Disease Treatment Introduction
  • 12.7.4 Idorsia Pharmaceuticals Ltd. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.7.5 Idorsia Pharmaceuticals Ltd. Recent Development
• 12.8 Avrobio Inc.
  • 12.8.1 Avrobio Inc. Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Fabry Disease Treatment Introduction
  • 12.8.4 Avrobio Inc. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.8.5 Avrobio Inc. Recent Development
• 12.9 Greenovation Biotech GmbH
  • 12.9.1 Greenovation Biotech GmbH Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Fabry Disease Treatment Introduction
  • 12.9.4 Greenovation Biotech GmbH Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.9.5 Greenovation Biotech GmbH Recent Development
• 12.10 Moderna Therapeutics Inc.
  • 12.10.1 Moderna Therapeutics Inc. Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Fabry Disease Treatment Introduction
  • 12.10.4 Moderna Therapeutics Inc. Revenue in Fabry Disease Treatment Business (2014-2019)
  • 12.10.5 Moderna Therapeutics Inc. Recent Development
• 12.11 Green Cross Pharma Pte Ltd.

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.
In 2018, the global Fabry Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Fabry Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Fabry Disease Treatment development in United States, Europe and China.

The key players covered in this study
Sanofi S.A.
Shire Plc.
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Greenovation Biotech GmbH
Moderna Therapeutics Inc.
Green Cross Pharma Pte Ltd.

Market segment by Type, the product can be split into
Enzyme Replacement Therapy (ERT)
Chaperone Treatment
Substrate Reduction Therapy (SRT)
Others

Market segment by Application, split into
Hospital
Clinic
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Fabry Disease Treatment status, future forecast, growth opportunity, key market and key players.
To present the Fabry Disease Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Fabry Disease Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.